Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Oncotarget ; 7(34): 55128-55140, 2016 Aug 23.
Artigo em Inglês | MEDLINE | ID: mdl-27391157

RESUMO

The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway is frequently hyper-activated upon vemurafenib treatment of melanoma. We have here investigated the relationship between SRY-box 10 (SOX10), forkhead box 3 (FOXD3) and microphthalmia-associated transcription factor (MITF) in the regulation of the receptor tyrosine-protein kinase ERBB3, and its cognate ligand neuregulin 1-beta (NRG1-beta). We found that both NRG1-beta and ERBB3 mRNA levels were elevated as a consequence of MITF depletion, induced by either vemurafenib or MITF small interfering RNA (siRNA) treatment. Elevation of ERBB3 receptor expression after MITF depletion caused increased activation of the PI3K pathway in the presence of NRG1-beta ligand. Together, our results suggest that MITF may play a role in the development of acquired drug resistance through hyper-activation of the PI3K pathway.


Assuntos
Melanoma/tratamento farmacológico , Fator de Transcrição Associado à Microftalmia/fisiologia , Neuregulina-1/análise , Receptor ErbB-3/análise , Linhagem Celular Tumoral , Fatores de Transcrição Forkhead/análise , Humanos , Indóis/farmacologia , Indóis/uso terapêutico , Melanoma/metabolismo , Fator de Transcrição Associado à Microftalmia/análise , Fosfatidilinositol 3-Quinases/fisiologia , Proteínas Proto-Oncogênicas c-akt/metabolismo , Fatores de Transcrição SOXE/análise , Transdução de Sinais/fisiologia , Sulfonamidas/farmacologia , Sulfonamidas/uso terapêutico , Vemurafenib
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...